Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Deloitte
QuintilesIMS
Queensland Health
Teva
AstraZeneca
Colorcon
UBS
Mallinckrodt
McKinsey

Generated: January 20, 2018

DrugPatentWatch Database Preview

PANRETIN Drug Profile

« Back to Dashboard

When do Panretin patents expire, and what generic alternatives are available?

Panretin is a drug marketed by Eisai Inc and is included in one NDA. There is one patent protecting this drug.

This drug has nineteen patent family members in eleven countries.

The generic ingredient in PANRETIN is alitretinoin. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alitretinoin profile page.
Summary for PANRETIN
Drug patent expirations by year for PANRETIN
Pharmacology for PANRETIN
Ingredient-typeRetinoids
Drug ClassRetinoid

US Patents and Regulatory Information for PANRETIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc PANRETIN alitretinoin GEL;TOPICAL 020886-001 Feb 2, 1999 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for PANRETIN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,056,954 Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor ➤ Subscribe
5,968,989 Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor ➤ Subscribe
6,506,917 Compounds and compositions useful for modulation of processes mediated by RXR ➤ Subscribe
6,992,108 Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor ➤ Subscribe
6,576,676 Means for the modulation of processes mediated by retinold receptors and compounds useful therefor ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for PANRETIN

Supplementary Protection Certificates for PANRETIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00043 Netherlands ➤ Subscribe PRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011
C/GB01/014 United Kingdom ➤ Subscribe PRODUCT NAME: ALITRETINOIN; REGISTERED: UK EU/1/00/149/001 20001018
/2001 Austria ➤ Subscribe PRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
01/009 Ireland ➤ Subscribe PRODUCT NAME: PANRETIN-ALITRETINOIN
2001 00012 Denmark ➤ Subscribe
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
McKinsey
Novartis
Chinese Patent Office
McKesson
Deloitte
Farmers Insurance
Fish and Richardson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot